NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Follow-Up Questions
NTHI 주식의 가격 성능은 어떻습니까?
NTHI의 현재 가격은 $12.09이며, 전 거래일에 decreased 0% 하였습니다.
NeOnc Technologies Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
NeOnc Technologies Holdings Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
NeOnc Technologies Holdings Inc의 시가총액은 얼마입니까?
NeOnc Technologies Holdings Inc의 현재 시가총액은 $231.6M입니다
